Vicarious Surgical updates corporate presentation, targeting 2025 launch vs $150B market

Vicarious Surgical Inc.

$150B addressable abdominal market; 96% of procedures still manual per company estimates.
Partnerships with three leading health systems (HCA, UPMC, etc.) covering >200 hospitals.
Roadmap: Beta 2 build in 2023, version 1.0 design lock and FDA De Novo submission in 2024.
First clinical patient expected in 2024, commercial launch targeted for 2025.
Decoupled actuator technology enables 1.8cm single-port access with 13 degrees of freedom per arm.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.